SOURCE: Protectus Medical Devices, Inc.

September 20, 2010 14:02 ET

Protectus Medical Devices CEO Addresses Development and Advantages of Protectus Medical Safety Syringe

MINNEAPOLIS, MN--(Marketwire - September 20, 2010) -  Dr. John Salstrom, President and CEO of Protectus Medical Devices, Inc. (OTCQB: PTMD) (PINKSHEETS: PTMD), which designs, engineers, and manufactures safety needle devices to protect healthcare workers from accidental needlestick injuries, was recently interviewed by The Investor Relations Group of New York City to discuss the Protectus Medical Safety Syringe.

In the interview, Dr. Salstrom discussed Protectus' safety syringe technology, which allows the user to be protected from needlestick injuries in the workplace. He outlined the high rate of accidental needlestick injuries in the US and the attendant high costs of follow-up needlestick reporting, assays and treatment. He also detailed the mechanics of the Protectus safety syringe's automatic, self-sheathing mechanism, which makes it an attractive and clear alternative to existing safety syringes. As well, he outlined the steps the Company followed to obtain 510(k) approval for the syringe as mandated by the US Food and Drug Administration. In addition, Dr. Salstrom discussed the relationship between Protectus and the Synergistic Medical Network, which has targeted individual doctors' offices, as well as larger hospital systems, across all 50 states in order to raise awareness of the advantages of the Protectus syringe. Further along, he explained the criteria Protectus used to select a manufacturer for the syringe, and concluded by outlining why Protectus is an attractive choice for potential investors. 

To watch the interview in its entirety, please visit the following link:

And also on our website:

About Protectus Medical Devices, Inc.
Protectus Medical Devices, Inc. (OTCQB: PTMD) (PINKSHEETS: PTMD) designs, engineers, and manufactures safety needle devices to protect healthcare workers from accidental needlestick injuries. It offers the Protectus Safety Syringe (formerly SquareOne Safety Syringe), a patented, automatic, self-sheathing hypodermic safety syringe designed to reduce or eliminate the dangers of accidental needlestick injuries to medical professionals worldwide who may be pricked, scraped or injected by a needle before or after it has been injected and withdrawn from patients potentially carrying infectious bloodborne microorganisms. The company has received 510(k) permission from the US FDA to manufacture and market its Safety Syringe in the US. No other permissions are required to manufacture and market the device. The company was founded in 1999 and is based in Minneapolis, Minnesota. For more information please visit

Forward-Looking Statements
This release contains "forward-looking statements" for purposes of the Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. These forward-looking statements are subject to various risks and uncertainties that could cause the business and financial results of Protectus Medical Devices, Inc. to differ materially from those currently anticipated, including the risk factors identified in the filings of Protectus Medical Devices, Inc. with the Securities and Exchange Commission.

Contact Information

  • Contact:
    John S. Salstrom, Ph.D.
    President and CEO
    Protectus Medical Devices, Inc.

    The Investor Relations Group
    Adam Holdsworth or James Carbonara